innovaTV 301 / ENGOT cx12

Name No. For Patients with Purpose
innovaTV 301 / ENGOT cx12 19-02

Second or Third-Line Recurrent or Metastatic Cervical Cancer

Tisotumab vedotin is an antibody-drug conjugate targeting tissue factor (TF). Preliminary safety and
efficacy data demonstrate the potential for tisotumab vedotin to substantially improve clinical
outcomes with a manageable safety profile in subjects with recurrent/metastatic cervical cancer
(r/mCC) who have received 1 or 2 prior lines of chemotherapy. The purpose of this trial is to evaluate
the efficacy of tisotumab vedotin compared to investigator’s choice of chemotherapy in subjects with
r/mCC who have received 1 or 2 prior lines of systemic therapy for their recurrent or metastatic

ENGOT-en15/ KEYNOTE-C93-00/ GOG-3064

Name No. For Patients with Purpose
ENGOT-en15/ KEYNOTE-C93-00/ GOG-3064 22-02

Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting

The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy.


Name No. For Patients with Purpose
ENGOT-ov65 / KEYNOTE-B96 22-03

Platinum resistant Recurrent Ovarian Cancer (PROT)

Patients can have epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with 1-2 prior lines of systemic therapy, including at least 1 prior platinum-based therapy with ≥4 cycles in first line.

The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival.


Name No. For Patients with Purpose
OVHIPEC-2 20-07

Stage III Epithelial Ovarian Cancer

The objective of this study is to prove that treatment with primary cytoreductive surgery in combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive surgery without HIPEC (standard arm)